Catalent, the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is to acquire Paragon Bioservices, a leading viral vector development and manufacturing partner for gene therapies, for $1.2bn. "Paragon's unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth. Paragon brings to Catalent a complementary capability that will fundamentally enhance our biologics business and our end-to-end integrated biopharmaceutical solutions for customers," said John Chiminski, Catalent's Chair & Chief Executive Officer. "We look forward to working with Paragon's incredibly talented team and world-class customers to complete the significant ongoing investments into expanded state-of-the-art facilities and deliver revolutionary, lifesaving treatments to patients."